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OBJECTIVES In this study, we sought to assess safety of symptom-limited exercise stress tests the day after
coronary stenting.
BACKGROUND Isolated cases of coronary stent thrombosis have been linked to early exercise stress testing,
thereby questioning the safety of unrestricted physical activity after the coronary procedure.
METHODS At a single center, 1,000 patients were randomized to a symptom-limited stress test the day
after coronary stenting or no stress test. The antiplatelet regimen consisted of acetylsalicylic
acid and postprocedural ticlopidine or clopidogrel. The primary end point of the study was the
incidence of clinical stent thrombosis at 14 days. The secondary end point was the occurrence
of access site complications.
RESULTS Clinical stent thrombosis occurred in five patients (1%) undergoing stress test and in five
patients (1%) randomized to no stress test (p  1.0). Access site complications were detected
in 4% and 5.2% of cases, respectively (p  0.37).
CONCLUSIONS Symptom-limited exercise stress testing the day after coronary stenting does not increase the
risk of clinical stent thrombosis or access site complications. Further investigations on safety
of early vigorous exercise after coronary stenting in a non-supervised setting are
warranted. (J Am Coll Cardiol 2003;42:1569–73) © 2003 by the American College of
Cardiology Foundation
Isolated cases of acute ischemic events linked to exercise
stress testing have been described after coronary stenting
(1–4). An exercise-induced systemic prothrombotic state in
conjunction with the intrinsic thrombogenicity of the stent
have been postulated as trigger mechanisms. These reports
have led to uncertainty among patients and physicians
regarding resumption of normal physical activity after cor-
onary stenting. With modern antiplatelet therapy, stent
thrombosis is a rare event, albeit associated with high
mortality (5). In order to address safety of unrestricted
physical activity after coronary stenting, we randomized
patients to stress test or no stress test the day after the
coronary procedure.
METHODS
Patient selection. At the Swiss Cardiovascular Center in
Bern, exercise stress testing after percutaneous coronary
revascularization is frequently performed. Between Septem-
ber 1997 and June 2001, a total of 1,000 patients (788
males, 212 females) were randomized to a symptom-limited
exercise stress test the day after coronary stenting or no
stress test. Clinical exclusion criteria were recent or ongoing
myocardial infarction (MI) (i.e., within one week), symp-
tomatic heart failure, severe valvular heart or pulmonary
disease, or inability to exercise. Periprocedural exclusion
criteria included symptomatic main vessel or side branch
occlusions, access site-related complications, persistent
chest pain or new ST-segment deviation, or final coronary
flow less than TIMI (Thrombolysis In Myocardial Infarc-
tion) grade 3. Access site complications were defined as one
of the following: pseudoaneurysm, arteriovenous fistula,
deep vein thrombosis or pulmonary embolism, need for
surgical repair of the access site, need for blood transfusion,
or the presence of a hematoma requiring prolonged or
repeat compressive measures to achieve hemostasis, pro-
longed hospital stay, or surgical revision. Coronary disease
was considered significant if the stenoses were visually
estimated at 50%. Suboptimal procedural results included
residual stenosis 50%, non–flow-limiting dissections, and
side-branch compromise in the absence of flow impairment.
Interventional technique. All the patients had femoral
access unless contraindicated. Percutaneous coronary inter-
vention was performed using 6F guiding catheters and
5,000 to 10,000 U of unfractionated heparin, without
monitoring of the periprocedural activated clotting time.
Acetylsalicylic acid 500 mg intravenously was administered
before the procedure in patients who were not undergoing
long-term therapy. Oral ticlopidine (250 mg twice a day for
two weeks) or clopidogrel (300 mg followed by 75 mg a day
for two to four weeks) was prescribed after stenting. The use
of adjunctive platelet glycoprotein (GP) IIb/IIIa receptor
inhibitors was left to the discretion of the operator. Sheaths
were pulled 4 h or more after the intervention without
previous coagulation check, and manual compression was
applied. Patients were usually ambulated the next day.
Study design. Randomization occurred at the end of the
coronary procedure, in the absence of exclusion criteria.
Symptom-limited treadmill stress testing was performed the
following day, before discharge, using a modified Bruce
protocol. A physician obtained the follow-up by phone
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interview at 14 days. The primary end point of the study was
clinical stent thrombosis at 14 days, defined by one of the
following: angiographically documented stent thrombosis,
sudden death, any MI, or urgent target vessel revasculariza-
tion. The secondary end points consisted of access site
complications, as previously described.
Statistical analysis. Assuming a stent thrombosis rate at 14
days of 1% in the control group (5), and a clinical margin of
inferiority of an additional 1.65%, a sample size of 450
patients per arm was required to demonstrate non-
inferiority of the stress test arm, with a power of 80% and a
0.05 level of significance. The total sample size of 500
patients per arm accounts for patients missing the stress test.
Continuous variables are expressed as mean  standard
deviation, and differences between the two groups of pa-
tients were tested with the Student t test. Categorical data
are presented as percentages, and comparisons among the
groups were made with the chi-squared test. A value of p 
0.05 was considered statistically significant. Results were
analyzed on an intention-to-treat basis.
RESULTS
A total of 498 patients were randomized to stress test group,
and 502 patients to a no stress test group. The two groups
were well matched for baseline and procedural characteris-
tics (Table 1). A greater proportion of patients with unstable
angina (UA) in the non–stress-test group was the only
imbalance detected. Among patients randomized to stress
testing, 50 patients (10%) did not undergo the test but were
followed up as part of the stress-test group. The only
coronary event detected among them was an acute stent
thrombosis that occurred 2 h after the intervention, requir-
ing emergent percutaneous intervention. Other reasons not
to undergo a stress test were related (18 cases) or unrelated
(16 cases) to the coronary procedure. In an additional 16
cases, no reason was given for skipping the test (Fig. 1).
Among patients undergoing a stress test, the mean attained
working capacity was 9.6  2.5 MET (metabolic equiva-
lent; corresponding to a respiratory oxygen uptake of 3.5
ml/min/kg of body weight), the heart rate 130  21
beats/min, and the rate-pressure product (heart rate 
Abbreviations and Acronyms
GP  glycoprotein
MI  myocardial infarction
UA  unstable angina
Table 1. Baseline and Procedural Characteristics
Stress Test
(n  498)
Controls
(n  502)
Gender, %
Male 80 77
Female 20 23
Age, mean (SD), yrs 62.0 (10.5) 63.2 (11.0)
Coronary artery disease, %
1-vessel 39 43
2-vessel 36 33
3-vessel 25 24
Indication for angiogram, %
Stable angina 45 42
Unstable angina 22* 30
Prior myocardial infarction 12 9
Other 21 19
Procedural characteristics
Multivessel intervention, % 22 20
Multivessel stenting, % 9 8
Glycoprotein IIb/IIIa receptor inhibitors, % 12 16
Ticlopidine, % 27 27
Clopidogrel, % 73 73
Stent per patient, mean (SD) 1.4 (0.8) 1.3 (0.7)
Stent diameter, mean (SD), mm 3.1 (0.5) 3.1 (0.4)
Total stent length, mean (SD), mm 19 (11) 19 (11)
Stented territory, %
Left anterior descending coronary artery 42 44
Left circumflex coronary artery 20 21
Right coronary artery 35 32
Bypass graft 2 2
Left main trunk 1 1
Suboptimal procedural result, % 9 9
Coronary 1-vessel, 2-vessel, or 3-vessel disease was defined based on the presence of at least one stenosis 50% per territory on
angiogram. Angiographic result was considered suboptimal in the presence of residual stenosis 50%, non-flow-limiting
dissections, or side-branch compromise in the absence of flow impairment. *p 0.01; for all other comparisons p nonsignificant.
1570 Roffi et al. JACC Vol. 42, No. 9, 2003
Exercise After Stenting November 5, 2003:1569–73
systolic blood pressure) 23,500  6,000. Adverse events
during stress test included a syncope at maximal workload in
the absence of rhythm disturbances, and a transient ST-
segment elevation in a patient with known coronary spasm.
No repeat angiograms were performed in these two patients,
and they remained free of cardiac events during follow-up.
Follow-up was completed in 99.5% of cases. The primary
end point, clinical stent thrombosis within 14 days, occurred
in five cases each of patients undergoing stress test (1%) or
randomized to no stress test (1%) (p  1) (Table 2). Events
occurred on day 0 (2 h after intervention), day 1, day 3, day
6, and day 9 in the stress-test group; and on day 0 (1 and
12 h after intervention), day 4, and day 6 in the no-stress-
test group. In one patient randomized to the no stress test
group, stent thrombosis could not be timed. It was docu-
mented incidentally during an elective angiogram per-
formed on day 9 for a staged revascularization. One patient
had anterior ST-segment elevation and left anterior de-
Figure 1. Flowchart of study patients. ECG  electrocardiographic.
Table 2. Clinical Events at 14-Day Follow-Up
Stress Test
(n  496)
Controls
(n  499)
Clinical stent thrombosis, no. (%)
Acute thrombosis (12 h) 1 (0.2) 1 (0.2)
Subacute thrombosis (12 h) 4 (0.8) 4 (0.8)
Any thrombosis 5 (1.0) 5 (1.0)
Access site complications, no. (%)
Pseudoaneurysm 2 (0.4) 3 (0.6)
Arteriovenous fistula 0 1 (0.2)
Deep vein thrombosis/pulmonary embolism 1 (0.2) 1 (0.2)
Surgical repair 1 (0.2) 2 (0.4)
Blood transfusions 0 1 (0.2)
Hematoma 17 (3.4) 21 (4.3)
Any access site complication 20 (4.0) 26 (5.2)
Hematoma was defined as femoral bleeding requiring prolonged or repeat compressive measures to achieve hemostasis,
prolonged hospitalization, or surgical revision. The p value is nonsignificant for all comparisons.
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scending coronary artery stent thrombosis 30 min after a
negative stress test. The indication for stenting had been
UA. He was treated with acetylsalicylic acid and ticlopidine.
He had not received GP IIb/IIIa receptor inhibitors during
the procedure. Despite immediate successful recanalization,
the patient developed anterior MI. Vascular access site
complications were comparable in both groups (4.0% with
and 5.8% without stress test, p  0.37) (Table 2).
No difference was observed in the clinical stent occlusion
rate in patients receiving ticlopidine (1.5%) or clopidogrel
(0.8%) (p  0.34). Patients who received platelet GP
IIb/IIIa receptor inhibitors during the coronary procedure
had a stent thrombosis rate of 1.4%. The occlusion rate of
those who did not was 0.9% (p  0.60). Among 254
patients undergoing coronary stenting for UA, eight pa-
tients (3.1%) had stent thrombosis, compared with two
patients (0.3%) among 741 stable patients (p  0.01). A
total of 89 patients had suboptimal periprocedural result and
an incidence of stent thrombosis of 3.4%, compared with
0.8% among 906 patients with good angiographic results
(p 0.02). When compared with patients who did not have
an event, those with stent thrombosis presented more
frequently with UA, received more stents, had a significantly
greater total stent length, and more frequently had a
suboptimal angiographic result after the procedure
(Table 3).
DISCUSSION
Addressing the safety of early physical exertion after coro-
nary stenting is crucial for medical and legal reasons (e.g.,
counseling of patients with physically challenging activities).
A total of four cases of stent occlusion linked to exercise
testing have been reported in the literature (1–4). Among
them, one patient was receiving coumadin (2); one was
receiving acetylsalicylic acid, dipyridamole, and heparin
while oral anticoagulation with acenocoumarol was started
(1); one was receiving acetylsalicylic acid and ticlopidine (4);
and in one case the antithrombotic regimen was not
described (3). The latency period between stenting and the
exercise stress test varied between two days and three
months, and the occurrence of stent occlusion ranged from
15 min to 2 h after the stress test. These observations may
lead to questions about the safety of heavy physical activity
for an extended period of time after coronary stenting.
An exercise-induced systemic prothrombotic state in
conjunction with the intrinsic thrombogenicity of the stent
have been postulated as trigger mechanisms of stent throm-
bosis. Despite the paucity of evidence that exercise may be
related to stent thrombosis, the belief that early stress tests
after coronary stenting may be hazardous is not uncommon
among physicians. According to the American College of
Cardiology/American Heart Association guidelines, the
safety of exercise stress testing after discharge in patients
who have undergone percutaneous coronary revasculari-
zation has not been established. Notwithstanding, the
procedure is considered a class IIa indication (i.e., weight of
evidence/opinion is in favor of usefulness/efficacy) for
activity counseling or exercise training as part of cardiac
rehabilitation (6).
This randomized trial shows that an early symptom-
limited exercise stress test does not increase the incidence of
clinical stent thrombosis or access site complications. The
clinical stent thrombosis rate observed was comparable with
previous reports (5,7,8). As in previous observations, pa-
tients with UA and those with a suboptimal procedural
result had an increased incidence of stent occlusion. In a
pooled analysis of stent trials including more than 6,000
patients, patients with stent thrombosis had presented more
frequently with UA (5). With respect to suboptimal proce-
dural results, a recent retrospective analysis demonstrated
that the vast majority of patients with stent thrombosis had
at least one abnormal feature detected by intravascular
ultrasound at the time of stent deployment (9). When
compared with patients who did not have an event, those
who had clinical stent thrombosis in our study received
more stents per patient and had significantly longer stented
coronary segments. This is in accordance with the existing
literature showing that total stent length is an independent
predictor of stent thrombosis (5).
Our data expand the findings of a nonrandomized series
Table 3. Patient Characteristics According to the Occurrence of Stent Thrombosis
Thrombosis
(n  10)
No Thrombosis
(n  985) p Value
Age, mean (SD), yrs 64.5 (11.7) 62.5 (10.7) 0.56
Female gender, no. (%) 1 (10) 210 (21) 0.38
Unstable angina, no. (%) 8 (80) 246 (25)  0.01
LAD stenting, no. (%) 7 (70) 437 (44) 0.10
Multivessel stenting, no. (%) 2 (20) 83 (8.4) 0.19
Stent number, mean (SD) 1.9 (1.3) 1.4 (0.7) 0.02
Total stent length, mean (SD), mm 33 (26) 19 (11)  0.01
Multivessel stenting, no. (%) 2 (20) 83 (8) 0.19
Clopidogrel, no. (%) 6 (60) 722 (73) 0.34
GP IIb/IIIa inhibitors, no. (%) 2 (20) 140 (14) 0.60
Suboptimal procedural result, no. (%) 3 (30) 86 (9) 0.02
Angiographic result was considered suboptimal in the presence of residual stenosis 50%, non-flow-limiting dissections, or
side-branch compromise in the absence of flow impairment.
GP IIb/IIIa inhibitors  platelet glycoprotein IIb/IIIa receptor inhibitors; LAD  left anterior descending coronary artery.
1572 Roffi et al. JACC Vol. 42, No. 9, 2003
Exercise After Stenting November 5, 2003:1569–73
reporting no complication among 261 patients undergoing
exercise stress test within 60 days of stent deployment (10).
The one-stent thrombosis after the stress test observed in
our study could arguably have been avoided by not perform-
ing the test. However, it is also possible that it would have
occurred spontaneously or at the first strenuous physical
activity. Outside the hospital setting, the medical manage-
ment of this complication would have been more difficult.
Study limitations. Limitations of the study include the fact
that roughly half of the 2,086 patients undergoing coronary
stent implantation at our institution during the trial period
were not enrolled, mainly because only selected physicians
participated in the trial. In addition, events were recorded
only up to 14 days. Yet, it is known that the vast majority of
stent thromboses occur within this period of time. More-
over, patients or referring physicians may have under-
reported access site-related complications occurring after
hospital discharge. Finally, the study protocol did not
mandate tracking of femoral access closure devices, because
at the beginning of the trial they were not used at our
institution. According to the practice during the time period
of the study, all procedures were performed using 6F
guiding catheters, and only a small minority of patients may
have received closure devices. Therefore, our findings on
access site complications may not apply to practices based
on larger sheath use or extensive closure device utilization.
Conclusions. In our randomized trial enrolling 1,000 pa-
tients, symptom-limited exercise stress testing the first day
after coronary stenting did not increase the risk for stent
thrombosis or access site complications. Further investiga-
tions on safety of early vigorous exercise after coronary
stenting in a non-supervised setting are warranted.
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